Autologous Blood Transfusion in Sports: Emerging Biomarkers

Transfusion Medicine Reviews

Volumn 30, Issue 3, 2016, Pages 109-115

  Salamin, Olivier ^a   De Angelis, Sara ^a   Tissot, Jean Daniel ^b   Saugy, Martial ^a   Leuenberger, Nicolas ^a  

^a UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^b laboratoire de recherche sur les produits sanguins   (Switzerland)

Author keywords

omics methods; Athlete biological passport; Biomarkers; Blood doping; Blood transfusions

Indexed keywords

BIOLOGICAL MARKER; IRON; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PLASTICIZER;

BIOMICS; BLOOD AUTOTRANSFUSION; HEMATOLOGICAL PARAMETERS; HUMAN; IRONOMICS; PROTEOMICS; REVIEW; SPORT; TRANSCRIPTOMICS; URINE; BLOOD; BLOOD STORAGE; CYTOLOGY; DOPING; ERYTHROCYTE; GENE EXPRESSION PROFILING;

BIOMARKERS; BLOOD PRESERVATION; BLOOD TRANSFUSION, AUTOLOGOUS; DOPING IN SPORTS; ERYTHROCYTES; GENE EXPRESSION PROFILING; HUMANS; PROTEOMICS; SPORTS;

EID: 84973549367     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2016.05.007     Document Type: Review

References (92)

1. The World Anti-Doping Agency The 2016 prohibited list, internation standard [accessed 01.03.2016]. https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2016-prohibited-list-en.pdf.
2. Lasne F, de Ceaurriz J Recombinant erythropoietin in urine. Nature 2000, 405:635.
3. Lasne F, Martin L, Crepin N, de Ceaurriz J Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 2002, 311:119-126.
4. Soule B, Lestrelin L The Puerto affair: revealing the difficulties of the fight against doping. J Sport Soc Issues 2011, 35:186-208.
5. Nelson M, Popp H, Sharpe K, Ashenden M Proof of homologous blood transfusion through quantification of blood group antigens. Haematologica 2003, 88:1284-1295.
6. Voss SC, Thevis M, Schinkothe T, Schanzer W Detection of homologous blood transfusion. Int J Sports Med 2007, 28:633-637.
7. Krotov G, Nikitina M, Rodchenkov G Possible cause of lack of positive samples on homologous blood transfusion. Drug Test Anal 2014, 6:1160-1162.
8. Sottas PE, Robinson N, Saugy M The athlete's biological passport and indirect markers of blood doping. Handb Exp Pharmacol 2010, 195:305-326.
9. Ashenden M, Gough CE, Garnham A, Gore CJ, Sharpe K Current markers of the athlete blood passport do not flag microdose EPO doping. Eur J Appl Physiol 2011, 111:2307-2314.
10. Lippi G, Plebani M, Sanchis-Gomar F, Banfi G Current limitations and future perspectives of the athlete blood passport. Eur J Appl Physiol 2012, 112:3693-3694.
11. Sottas PE, Vernec A Current implementation and future of the athlete biological passport. Bioanalysis 2012, 4:1645-1652.
12. Sottas PE, Robinson N, Rabin O, Saugy M The athlete biological passport. Clin Chem 2011, 57:969-976.
13. Pottgiesser T, Schumacher YO Current strategies of blood doping detection. Anal Bioanal Chem 2013, 405:9625-9639.
14. Schumacher YO, Saugy M, Pottgiesser T, Robinson N Detection of EPO doping and blood doping: the haematological module of the athlete biological passport. Drug Test Anal 2012, 4:846-853.
15. Saugy M, Lundby C, Robinson N Monitoring of biological markers indicative of doping: the athlete biological passport. Br J Sports Med 2014, 48:827-832.
16. Pottgiesser T, Sottas PE, Echteler T, Robinson N, Umhau M, Schumacher YO Detection of autologous blood doping with adaptively evaluated biomarkers of doping: a longitudinal blinded study. Transfusion 2011, 51:1707-1715.
17. Pottgiesser T, Echteler T, Sottas PE, Umhau M, Schumacher YO Hemoglobin mass and biological passport for the detection of autologous blood doping. Med Sci Sports Exerc 2012, 44:835-843.
18. Morkeberg J, Sharpe K, Belhage B, Damsgaard R, Schmidt W, Prommer N, et al. Detecting autologous blood transfusions: a comparison of three passport approaches and four blood markers. Scand J Med Sci Sports 2011, 21:235-243.
19. Ashenden M, Morkeberg J Net haemoglobin increase from reinfusion of refrigerated vs. frozen red blood cells after autologous blood transfusions. Vox Sang 2011, 101:320-326.
20. Lundby C, Robach P Assessment of total haemoglobin mass: can it detect erythropoietin-induced blood manipulations?. Eur J Appl Physiol 2010, 108:197-200.
21. Morkeberg J Detection of autologous blood transfusions in athletes: a historical perspective. Transfus Med Rev 2012, 26:199-208.
22. Prommer N, Sottas PE, Schoch C, Schumacher YO, Schmidt W Total hemoglobin mass-a new parameter to detect blood doping?. Med Sci Sports Exerc 2008, 40:2112-2118.
23. Segura J, Monfort N, Ventura R Detection methods for autologous blood doping. Drug Test Anal 2012, 4:876-881.
24. Pottgiesser T, Schumacher YO, Funke H, Rennert K, Baumstark MW, Neunuebel K, et al. Gene expression in the detection of autologous blood transfusion in sports-a pilot study. Vox Sang 2009, 96:333-336.
25. Segura J, Lundby C Blood doping: potential of blood and urine sampling to detect autologous transfusion. Br J Sports Med 2014, 48:837-841.
26. Fan H, Hegde PS The transcriptome in blood: challenges and solutions for robust expression profiling. Curr Mol Med 2005, 5:3-10.
27. Lee E, Choi HS, Hwang JH, Hoh JK, Cho YH, Baek EJ The RNA in reticulocytes is not just debris: it is necessary for the final stages of erythrocyte formation. Blood Cells Mol Dis 2014, 53:1-10.
28. Varlet-Marie E, Audran M, Ashenden M, Sicart MT, Piquermal D Modification of gene expression: help to detect doping with erythropoiesis-stimulating agents. Am J Hematol 2009, 84:755-759.
29. Durussel J, Haile DW, Mooses K, Daskalai E, Beattie W, Mooses M, et al. The blood transcriptional signature of recombinant human erythropoietin administration and implications for anti-doping strategies. Physiol Genomics 2016, 48:202-209.
30. Leuenberger N, Schumacher YO, Pradervand S, Sander T, Saugy M, Pottgiesser T Circulating microRNAs as biomarkers for detection of autologous blood transfusion. PLoS One 2013, 8:e66309.
31. Szoke D, Panteghini M Diagnostic value of transferrin. Clin Chim Acta 2012, 413:1184-1189.
32. Leuenberger N, Barras L, Nicoli R, Robinson N, Baume N, Lion N, et al. Hepcidin as a new biomarker for detecting autologous blood transfusion. Am J Hematol 2016, 91:467-472.
33. Saxena S, Shulman IA, Johnson C Effect of blood transfusion on serum iron and transferrin saturation. Arch Pathol Lab Med 1993, 117:622-624.
34. Harms K, Kaiser T Beyond soluble transferrin receptor: old challenges and new horizons. Best Pract Res Clin Endocrinol Metab 2015, 29:799-810.
35. Dehnes Y, Hemmersbach P Effect of single doses of methoxypolyethylene glycol-epoetin beta (CERA, Mircera) and epoetin delta (Dynepo) on isoelectric erythropoietin profiles and haematological parameters. Drug Test Anal 2011, 3:291-299.
36. Robach P, Recalcati S, Girelli D, Campostrini N, Kempf T, Wollert KC, et al. Serum hepcidin levels and muscle iron proteins in humans injected with low- or high-dose erythropoietin. Eur J Haematol 2013, 91:74-84.
37. Damsgaard R, Munch T, Morkeberg J, Mortensen SP, Gonzalez-Alonso J Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: implications for anti-doping strategies. Haematologica 2006, 91:1006-1008.
38. Berglund B, Birgegard G, Wide L, Pihlstedt P Effects of blood transfusions on some hematological variables in endurance athletes. Med Sci Sports Exerc 1989, 21:637-642.
39. Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat B, et al. Physiology of iron metabolism. Transfus Med Hemother 2014, 41:213-221.
40. Rochat B, Peduzzi D, McMullen J, Favre A, Kottelat E, Favrat B, et al. Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform. Bioanalysis 2013, 5:2509-2520.
41. Waldvogel S, Rochat B, Peduzzi D, Vaucher P, Tissot JD, Favrat B Effects of oral supplementation of iron on hepcidin blood concentrations among non-anaemic female blood donors: a randomized controlled trial. Vox Sang 2016, 110:166-171.
42. Pallotta V, Rinalducci S, Zolla L Red blood cell storage affects the stability of cytosolic native protein complexes. Transfusion 2015, 55:1927-1936.
43. Hod EA, Brittenham GM, Billote GB, Francis RO, Ginzburg YZ, Hendrickson JE, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood 2011, 118:6675-6682.
44. Leuenberger N, Ansermet C, Pottgiesser T, Baume N, Robinson N, Saugy M, et al. A fast automated screening method for the detection of blood transfusion in sports. Drug Test Anal 2014, 6:1141-1143.
45. Lippi G, Aloe R, Avanzini P, Banfi G Measurement of iron in serum and EDTA plasma for screening of blood transfusion in sports. Drug Test Anal 2015, 7:253-254.
46. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014, 46:678-684.
47. Monfort N, Ventura R, Latorre A, Belalcazar V, Lopez M, Segura J Urinary di-(2-ethylhexyl)phthalate metabolites in athletes as screening measure for illicit blood doping: a comparison study with patients receiving blood transfusion. Transfusion 2010, 50:145-149.
48. Koch HM, Preuss R, Angerer J Di(2-ethylhexyl)phthalate (DEHP): human metabolism and internal exposure-an update and latest results. Int J Androl 2006, 29:155-165. [discussion 181-5].
49. Monfort N, Ventura R, Balcells G, Segura J Determination of five di-(2-ethylhexyl)phthalate metabolites in urine by UPLC-MS/MS, markers of blood transfusion misuse in sports. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 908:113-121.
50. Leuenberger N, Barras L, Nicoli R, Robinson N, Baume N, Lion N, et al. Urinary di-(2-ethylhexyl) phthalate metabolites for detecting transfusion of autologous blood stored in plasticizer-free bags. Transfusion 2015, 56:571-578.
51. Solymos E, Guddat S, Geyer H, Flenker U, Thomas A, Segura J, et al. Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. Anal Bioanal Chem 2011, 401:517-528.
52. Guddat S, Solymos E, Orlovius A, Thomas A, Sigmund G, Geyer H, et al. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test Anal 2011, 3:836-850.
53. Badoud F, Grata E, Perrenoud L, Avois L, Saugy M, Rudaz S, et al. Fast analysis of doping agents in urine by ultra-high-pressure liquid chromatography-quadrupole time-of-flight mass spectrometry I. Screening analysis. J Chromatogr A 2009, 1216:4423-4433.
54. Fromme H, Bolte G, Koch HM, Angerer J, Boehmer S, Drexler H, et al. Occurrence and daily variation of phthalate metabolites in the urine of an adult population. Int J Hyg Environ Health 2007, 210:21-33.
55. Monfort N, Ventura R, Platen P, Hinrichs T, Brixius K, Schanzer W, et al. Plasticizers excreted in urine: indication of autologous blood transfusion in sports. Transfusion 2012, 52:647-657.
56. Solymos E, Guddat S, Geyer H, Thomas A, Thevis M, Schanzer W Di(2-ethylhexyl) phthalate metabolites as markers for blood transfusion in doping control: intra-individual variability of urinary concentrations. Drug Test Anal 2011, 3:892-895.
57. Prowse CV, de Korte D, Hess JR, van der Meer PF Commercially available blood storage containers. Vox Sang 2014, 106:1-13.
58. Tinmouth A, Chin-Yee I The clinical consequences of the red cell storage lesion. Transfus Med Rev 2001, 15:91-107.
59. D'Amici GM, Rinalducci S, Zolla L Proteomic analysis of RBC membrane protein degradation during blood storage. J Proteome Res 2007, 6:3242-3255.
60. D'Alessandro A, Liumbruno G, Grazzini G, Zolla L Red blood cell storage: the story so far. Blood Transfus 2010, 8:82-88.
61. Reichel C OMICS-strategies and methods in the fight against doping. Forensic Sci Int 2011, 213:20-34.
62. Liumbruno G, D'Amici GM, Grazzini G, Zolla L Transfusion medicine in the era of proteomics. J Proteomics 2008, 71:34-45.
63. Nikolovski Z, De La Torre C, Chiva C, Borras E, Andreu D, Ventura R, et al. Alterations of the erythrocyte membrane proteome and cytoskeleton network during storage-a possible tool to identify autologous blood transfusion. Drug Test Anal 2012, 4:882-890.
64. Rinalducci S, D'Amici GM, Blasi B, Vaglio S, Grazzini G, Zolla L Peroxiredoxin-2 as a candidate biomarker to test oxidative stress levels of stored red blood cells under blood bank conditions. Transfusion 2011, 51:1439-1449.
65. Marrocco C, Pallotta V, D'Alessandro A, Alves G, Zolla L Red blood cell populations and membrane levels of peroxiredoxin 2 as candidate biomarkers to reveal blood doping. Blood Transfus 2012, 10(Suppl. 2):s71-s77.
66. Prudent M, Crettaz D, Delobel J, Seghatchian J, Tissot JD, Lion N Differences between calcium-stimulated and storage-induced erythrocyte-derived microvesicles. Transfus Apher Sci 2015, 53:153-158.
67. Burns JM, Yoshida T, Dumont LJ, Yang X, Piety NZ, Shevkoplyas SS Deterioration of red blood cell mechanical properties is reduced in anaerobic storage. Blood Transfus 2016, 14:80-88.
68. Liu D, Albert PS Combination of longitudinal biomarkers in predicting binary events. Biostatistics 2014, 15:706-718.
69. Ashenden M, Varlet-Marie E, Lasne F, Audran M The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica 2006, 91:1143-1144.
70. Laine F, Laviolle B, Ropert M, Bouguen G, Morcet J, Hamon C, et al. Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers. Eur J Appl Physiol 2012, 112:1391-1397.
71. Burden RJ, Pollock N, Whyte GP, Richards T, Moore B, Busbridge M, et al. Effect of intravenous iron on aerobic capacity and iron metabolism in elite athletes. Med Sci Sports Exerc 2015, 47:1399-1407.
72. Garvican LA, Saunders PU, Cardoso T, Macdougall IC, Lobigs LM, Fazakereley R, et al. Intravenous iron supplementation in distance runners with low or suboptimal ferritin. Med Sci Sports Exerc 2014, 46:376-385.
73. Hinton PS, Sinclair LM Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2007, 61:30-39.
74. Friedmann B, Weller E, Mairbaurl H, Bartsch P Effects of iron repletion on blood volume and performance capacity in young athletes. Med Sci Sports Exerc 2001, 33:741-746.
75. Woods A, Garvican-Lewis LA, Saunders PU, Lovell G, Hughes D, Fazakerley R, et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. PLoS One 2014, 9:e108042.
76. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, et al. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Med 2012, 10:8.
77. Hinton PS, Giordano C, Brownlie T, Haas JD Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol 2000, 88:1103-1111.
78. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women-PREFER a randomized, placebo-controlled study. PLoS One 2014, 9:e94217.
79. Pitsis GC, Fallon KE, Fallon SK, Fazakerley R Response of soluble transferrin receptor and iron-related parameters to iron supplementation in elite, iron-depleted, nonanemic female athletes. Clin J Sport Med 2004, 14:300-304.
80. DellaValle D, Haas JD Iron supplementation improves energetic efficiency in iron-depleted female rowers. Med Sci Sports Exerc 2014, 46:1204-1215.
81. Brownlie T, Utermohlen V, Hinton PS, Haas JD Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004, 79:437-443.
82. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000, 85:564-572.
83. Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics 2001, 107:78-85.
84. Parisotto R, Wu M, Ashenden M, Emslie KR, Gore CJ, Howe C, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001, 86:128-137.
85. Lippi G, Banfi G Blood transfusions in athletes. Old dogmas, new tricks. Clin Chem Lab Med 2006, 44:1395-1402.
86. Morkeberg J, Belhage B, Ashenden M, Borno A, Sharpe K, Dziegiel MH, et al. Screening for autologous blood transfusions. Int J Sports Med 2009, 30:285-292.
87. Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood 2015, 126:2031-2037.
88. Mast AE, Schlumpf KS, Wright DJ, Johnson B, Glynn SA, Busch MP, et al. Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica 2013, 98:1324-1330.
89. Mast AE Low hemoglobin deferral in blood donors. Transfus Med Rev 2014, 28:18-22.
90. Aardal Eriksson E, Moback C, Jakobsson S, Hoffmann JJ Iron depletion in blood donors-have extended erythrocyte and reticulocyte parameters diagnostic utility?. Transfus Apher Sci 2015, 53:76-81.
91. Peffer K, den Heijer M, Holewijn S, de Graaf J, Swinkels DW, Verbeek AL, et al. The effect of frequent whole blood donation on ferritin, hepcidin, and subclinical atherosclerosis. Transfusion 2013, 53:1468-1474.
92. Pittori C, Buser A, Gasser UE, Sigle J, Job S, Ruesch M, et al. A pilot iron substitution programme in female blood donors with iron deficiency without anaemia. Vox Sang 2011, 100:303-311.